Drug Price Trends for ALTACE

Average Pharmacy Cost for ALTACE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALTACE 10 MG CAPSULE	61570-0120-01	7.46293	EACH	2025-07-23
ALTACE 10 MG CAPSULE	61570-0120-01	7.46543	EACH	2025-06-18

Altace (Ramipril) Market Analysis and Price Projections

Last updated: February 18, 2026

This report analyzes the market dynamics and price trajectory for Altace (ramipril), a widely prescribed angiotensin-converting enzyme (ACE) inhibitor. The analysis focuses on patent expiration, generic competition, market demand, and pricing strategies impacting its future accessibility and cost.

What is Altace and its Therapeutic Application?

Altace, the brand name for ramipril, is a medication belonging to the class of drugs known as ACE inhibitors. It is primarily prescribed for the treatment of hypertension (high blood pressure) and to improve survival after a heart attack. Ramipril works by relaxing blood vessels, which lowers blood pressure and reduces the workload on the heart. Its efficacy in managing cardiovascular conditions has established it as a significant player in the global pharmaceutical market.

What is the Patent Landscape for Altace?

The primary patent for ramipril, held by Aventis (now part of Sanofi), has long expired. The U.S. Patent 4,587,256, covering the compound ramipril, expired in January 2005. Subsequent patents related to specific formulations, manufacturing processes, or therapeutic uses also faced expiration or have been successfully challenged by generic manufacturers.

The expiration of key patents has opened the door for widespread generic competition, significantly impacting the market dynamics of Altace. Generic versions of ramipril are now readily available, offering a cost-effective alternative to the branded product.

How Has Generic Competition Affected Altace's Market Share and Pricing?

The introduction of generic ramipril has led to a substantial decline in the market share of branded Altace. Pharmaceutical data indicates that following patent expiry and the entry of multiple generic manufacturers, the market share of branded Altace has diminished considerably.

Comparative Pricing of Branded Altace vs. Generic Ramipril (USD)

Product Type	Average Wholesale Price (AWP) per 30-count bottle (2023 Est.)	Percentage Price Reduction vs. Branded Altace
Branded Altace	$150 - $200	N/A
Generic Ramipril	$20 - $50	70% - 85%

Note: AWP figures are estimates and can vary significantly based on pharmacy, insurance, and negotiated discounts.

This price erosion is a standard market response to generic entry. Manufacturers of generic ramipril can offer their products at significantly lower prices due to lower research and development costs and streamlined manufacturing processes. This has made ramipril more accessible to a broader patient population, particularly those in countries with strict healthcare cost controls or for patients with limited insurance coverage.

What is the Current Market Size and Demand for Ramipril?

The global market for ACE inhibitors, including ramipril, remains robust due to the high prevalence of cardiovascular diseases and hypertension worldwide. While specific figures for ramipril alone are proprietary, the broader ACE inhibitor market is estimated to be in the billions of dollars.

Key Market Drivers for Ramipril:

• High Prevalence of Hypertension: Cardiovascular diseases remain a leading cause of mortality globally. Hypertension affects a significant percentage of the adult population, creating a persistent demand for effective antihypertensive medications like ramipril. According to the World Health Organization (WHO), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension. [1]
• Post-Myocardial Infarction (MI) Treatment: Ramipril is indicated for improving survival in patients who have had a heart attack. The continued incidence of heart attacks globally sustains demand for such post-event therapies.
• Kidney Disease Management: ACE inhibitors, including ramipril, are often used to slow the progression of kidney disease, particularly in patients with diabetes or hypertension. This application adds another layer of demand.
• Cost-Effectiveness of Generics: The availability of low-cost generic ramipril makes it a preferred treatment option for healthcare systems and patients focused on cost containment.

The demand for ramipril, in its generic form, is projected to remain stable or see modest growth, driven by these underlying epidemiological trends and the drug's established therapeutic profile.

What are the Future Price Projections for Ramipril?

Given the mature status of ramipril, the absence of significant patent barriers, and established generic competition, dramatic price increases for generic ramipril are unlikely.

Factors Influencing Future Pricing:

• Manufacturing Costs: Raw material costs, energy prices, and labor expenses for active pharmaceutical ingredient (API) production will continue to be the primary determinants of manufacturing cost. These are generally stable with established supply chains.
• Competition Intensity: The number of generic manufacturers in the market will continue to influence pricing. A highly fragmented market with numerous suppliers tends to drive prices down. The ramipril market is characterized by several established generic players.
• Regulatory Landscape: Any changes in regulatory requirements for drug manufacturing or approval could potentially impact production costs, but significant shifts are not anticipated in the near term for established generic molecules.
• Healthcare Policy and Reimbursement: Government pricing regulations, payer negotiations, and formulary decisions will continue to exert downward pressure on prices. Many national health services prioritize cost-effective generic options.
• Emergence of New Therapies: While ramipril is a well-established drug, the development of novel cardiovascular therapies or improved drug delivery systems could, over the long term, influence its market position and thus pricing. However, for a drug with such a long history and widespread use, displacement by entirely new classes of drugs is typically a slow process.

Price Projection:

It is projected that the average price of generic ramipril will remain relatively stable in the coming years, with minor fluctuations driven by supply-demand dynamics and manufacturing costs. A slight downward trend or continued plateauing is more probable than a significant upward movement. We anticipate that the average price for a 30-count bottle of generic ramipril will likely remain within the $20 to $50 USD range, potentially trending towards the lower end of this spectrum in competitive markets.

What is the Competitive Landscape for Ramipril?

The competitive landscape for ramipril is dominated by generic manufacturers. Branded Altace holds a negligible market share in most regions. Key competitors in the generic ramipril market include:

• Teva Pharmaceuticals
• Mylan (now Viatris)
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Cipla
• Numerous other regional and global generic drug manufacturers.

These companies compete primarily on price, manufacturing efficiency, and distribution networks. Their ability to produce ramipril at scale and comply with regulatory standards allows them to offer competitive pricing.

Beyond direct generic competition, ramipril also competes with other classes of antihypertensive medications and other ACE inhibitors.

Key Competing Drug Classes:

• Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Olmesartan. These are often used as alternatives or in combination therapy, particularly for patients intolerant to ACE inhibitors.
• Calcium Channel Blockers (CCBs): Amlodipine, Diltiazem.
• Diuretics: Hydrochlorothiazide, Chlorthalidone.
• Beta-Blockers: Metoprolol, Atenolol.

While these classes offer alternative treatment options, ramipril's established efficacy, tolerability profile (for many patients), and cost-effectiveness ensure its continued place in therapeutic guidelines.

What are the Key Takeaways for Stakeholders?

• Generic Dominance: The market for ramipril is fully commoditized, with branded Altace having minimal market presence.
• Price Stability Expected: Generic ramipril prices are projected to remain stable or decline slightly, driven by manufacturing costs and intense competition. Significant price increases are not anticipated.
• Consistent Demand: Underlying health trends (hypertension, cardiovascular disease) ensure a sustained demand for ramipril, particularly in its generic form.
• Competitive Intensity: The market is highly competitive, with numerous global and regional generic manufacturers.
• Strategic Considerations: For pharmaceutical companies involved in ramipril manufacturing or distribution, the focus should be on operational efficiency, supply chain reliability, and market penetration rather than price inflation.

Frequently Asked Questions

1. Will the price of branded Altace increase significantly now that it is off-patent? No, the price of branded Altace is unlikely to increase significantly. With numerous generic alternatives available at substantially lower prices, the branded product's market share and pricing power are severely diminished. Manufacturers typically focus on maintaining market presence through established channels rather than aggressive price increases for legacy brands post-patent expiry.

2. Are there any new formulations or delivery methods of ramipril in development that could impact the market? While research into improved drug delivery is ongoing, there are no widely publicized or near-term developments for significantly novel ramipril formulations that are expected to disrupt the current generic market. Existing formulations are well-established and effective.

3. How does ramipril's market performance compare to other ACE inhibitors? Ramipril remains a strong contender among ACE inhibitors due to its efficacy and favorable safety profile for many patients. While other ACE inhibitors like enalapril and lisinopril also have significant generic presence, ramipril maintains a distinct market share driven by its specific indications and prescribing patterns. However, the overall market dynamics for all ACE inhibitors are similar, characterized by generic dominance and price sensitivity.

4. What is the impact of global supply chain issues on ramipril pricing? Global supply chain disruptions can lead to temporary price volatility or availability issues for various pharmaceutical products. For ramipril, if API production or finished dosage form manufacturing is significantly impacted, localized or temporary price increases or shortages could occur. However, the widespread availability of multiple manufacturers generally acts as a buffer against sustained, significant price inflation due to such issues for established generics.

5. Are there any upcoming patent expirations related to ramipril that could introduce new generic competition? The primary patents for the ramipril compound have expired decades ago. Any remaining patents are likely to be for specific formulations or manufacturing processes that have already been addressed or are nearing expiration without significant market impact. The window for new, impactful patent expirations that would introduce substantial new generic competition for ramipril has closed.

---

Citations

[1] World Health Organization. (n.d.). Hypertension. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension